Vera Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc. is a U.S.-listed biotechnology company traded on the NASDAQ under the ticker VERA. It is headquartered in Brisbane, California, United States. For French, Belgian, and Swiss investors, Vera is best viewed as a late-stage clinical biotech transitioning toward first commercialization, with no meaningful product revenue to date and a value proposition tied to clinical execution, regulatory milestones, and eventual market adoption. The company was originally founded under a different name and was renamed Vera Therapeutics in 2020. Since then, it has focused on serious immunological diseases, with a strong emphasis on autoimmune kidney disorders. Its lead strategic target is IgA nephropathy (IgAN), also known as Berger’s disease, a chronic kidney disease that can progressively impair renal function and ultimately lead to kidney failure in some patients. Vera’s stated mission is to change the standard of care by addressing the immune drivers of disease rather than only managing downstream symptoms. Vera’s principal asset is atacicept, a self-administered once-weekly subcutaneous fusion protein that blocks both BAFF and APRIL, two biologic pathways involved in B-cell and plasma-cell activation and autoantibody production. In investor terms, atacicept is the company’s key value driver and the asset most likely to determine whether Vera evolves from a development-stage biotech into a commercial specialty pharmaceutical company. The firm is also advancing MAU868, a monoclonal antibody designed to neutralize BK virus infection, an important complication in kidney transplant and other immunosuppressed settings. From a competitive standpoint, Vera operates in a highly selective niche where success depends on high-quality clinical data, regulatory timing, and the ability to translate late-stage trial results into a commercial launch. In IgAN, the company strengthened its profile in 2025 with positive Phase 3 ORIGIN data, which were presented at ASN Kidney Week and published in the New England Journal of Medicine. More recently, in January 2026, the U.S. FDA granted priority review to the BLA for atacicept in adult IgAN, with a PDUFA target action date of July 7, 2026. In its May 2026 business update, Vera said it remained on track for a U.S. commercial launch in mid-2026, pending approval, and highlighted a balance sheet expected to fund operations beyond potential approval and launch. Geographically, Vera remains primarily U.S.-focused, with corporate operations centered in California and a near-term commercialization strategy aimed at the United States market. For European investors, the stock represents a classic NASDAQ biotech catalyst story: concentrated pipeline exposure, significant binary regulatory risk, and potentially meaningful upside if atacicept clears FDA review and gains traction in IgAN.